Lawyers rush to halt Indiana execution over state’s lethal drug supplier

Lawyers are asking Gov. Mike Braun to halt Jeffrey Weisheit’s execution because they question how Indiana obtained the lethal-injection drugs. They argue that the state may have purchased pentobarbital from a pharmacy on probation and facing possible license suspension. They say this undermines confidence in a process that ends a person’s life for the state.

The concern centers on Pharmaneek, an Indianapolis pharmacy allegedly connected to a redacted Department of Correction invoice. Inspectors found expired drugs, unlabeled bottles, inconsistent temperature logs and possible unsanitary conditions. The state paid $275,000 for six vials, far above the usual commercial price. Weisheit’s lawyers also cite Tennessee’s failed execution of Christa Pike.

Weisheit did not contest his guilt but sought clemency, asking for life without parole. His attorneys want a reprieve and an independent review of Indiana’s procedures. The governor’s office declined to comment on the pharmacy allegations, while the Department of Correction did not respond to requests for comment.

Lethal injection is a method of carrying out a death sentence by administering drugs through an injection. The drugs are intended to produce unconsciousness and then cause death. The article focuses on Indiana’s use of pentobarbital, but it does not identify every drug or step in the state’s protocol.

Pentobarbital is a barbiturate, a class of drug that depresses activity in the central nervous system. In lethal-injection settings, it is used as the execution drug itself or as part of a drug sequence, depending on the protocol. Indiana’s inventory log showed six vials were added on Oct. 29. The state reportedly paid $275,000 for them.

The issue matters because Weisheit’s lawyers say Indiana’s protocol may be vulnerable to serious failure. They cited Tennessee’s Sept. 30 execution of Christa Pike, which left Pike in a coma after the procedure failed. The article does not establish that Indiana’s drugs are defective or that its execution would fail.

The reported price was $275,000 for six vials of pentobarbital. That figure appears on an invoice included in Weisheit’s application for a reprieve. The invoice is heavily redacted, so it does not show the transaction’s date or supplier.

The usual price for commercially made injectable pentobarbital is listed as $15,120 to $16,250. The reported Indiana payment is therefore roughly 17 to 18 times higher than that range. The comparison highlights how expensive and opaque the state’s acquisition may have been, though the article does not explain every reason for the difference.

An inventory log shows the six vials entered the Department of Correction’s supply on Oct. 29. A September 2025 invoice for the same amount corresponded to the previous addition of pentobarbital and accidentally revealed a possible supplier’s address. The address matched Pharmaneek, whose license and controlled-substance registration are on probation.

Inspections identified several problems at Pharmaneek, the Indianapolis pharmacy allegedly connected to Indiana’s execution-drug supply. Drugs were stored in unlabeled bottles. Inspectors also found expired drugs during a random check of active pharmacy shelves. The pharmacy failed to maintain consistent temperature logs for storage areas.

An FDA inspection report from March 2026 described the facility as not being maintained in a good state of repair. It said the conditions could allow drug products to be contaminated with filth. The report also stated that its findings were not a final agency determination of compliance. Pharmaneek attributed some problems to remodeling in a settlement agreement.

Indiana licensing records show the pharmacy’s license and controlled-substance registration are on probation. The Indiana Board of Pharmacy ordered Pharmaneek to appear and explain why its license should not be suspended on an emergency basis or face further sanctions. Pharmaneek did not respond to NBC News, and the article gives no final ruling.

Using drugs from a pharmacy on probation could affect an execution because regulators had already identified possible failures in storage, handling and facility conditions. Those failures raise questions about whether the drug was prepared and preserved reliably. In a state execution, doubts about the drug’s quality can become doubts about the fairness and safety of the entire process.

Pharmaneek was cited for unlabeled bottles, expired drugs, weak temperature records and possible unsanitary conditions. Its pharmacy license and controlled-substance registration were on probation. The Department of Correction invoice that allegedly points to Pharmaneek was heavily redacted, so the supplier connection remains described as possible.

Weisheit’s lawyers argue that these facts justify stopping the execution and conducting an independent review. They also say Indiana’s protocol may be more vulnerable to a catastrophic failure. The article does not establish that the pentobarbital was contaminated, ineffective or legally unusable, and it does not report a ruling on whether the execution could proceed.

States often keep execution-drug suppliers’ identities secret to protect participants and preserve access to drugs. The article specifically says Indiana law shields the identities of participants, pharmacies and suppliers involved in executions. More broadly, secrecy can reduce the risk of harassment or pressure against organizations connected to executions, though that rationale is not detailed in the article.

The secrecy creates an oversight conflict. Officials can protect suppliers’ identities, but the public and condemned prisoners may have less information about the drug’s source, cost and handling. In this case, a redacted invoice concealed the supplier. An address visible beneath the redaction matched Pharmaneek, allowing lawyers to identify a possible connection.

That disclosure became central to Weisheit’s reprieve request. His lawyers argue the process is unworthy of public confidence and needs independent review. The Department of Correction and governor’s office did not provide substantive answers, so the article leaves the supplier connection and its legal consequences unresolved.

Lethal-injection drugs sit at the intersection of pharmaceutical regulation and capital punishment. Regulators require drugs to meet safety and handling standards. Manufacturers may also limit distribution or object to their products being used in executions. These broader industry points are established background, not details provided by this article.

When ordinary manufacturers restrict access, states may turn to specialized or compounding pharmacies. Those pharmacies can face different oversight issues, including inspections, licensing conditions and storage requirements. Indiana’s case shows the risk: a possible supplier, Pharmaneek, had probationary licenses and inspection findings involving expired drugs, unlabeled bottles and temperature records.

Indiana law also keeps suppliers’ identities secret. That can help preserve access, but it makes outside checking more difficult. The state reportedly paid $275,000 for six vials, while the usual commercial price was $15,120 to $16,250. Weisheit’s lawyers want an independent review; the article reports no final decision about the drugs or execution.